ライフサイエンスコーパス: steroid withdrawal

1 ant in kidney transplant recipients on rapid steroid withdrawal.

2 y glucocorticoid taper in a regimen of early steroid withdrawal.

3 lta receptors, which are increased following steroid withdrawal.

4 its accompanying risk of acute rejection on steroid withdrawal.

5 , develop delayed graft function, or undergo steroid withdrawal.

6 w signature remained stable before and after steroid withdrawal.

7 mained viable and resumed proliferation upon steroid withdrawal.

8 dices were also observed in association with steroid withdrawal.

9 Of the 124 patients analyzed for steroid withdrawal, 1-, 2-, and 4-year patient survival

10 Relapses occurred in 53% after steroid withdrawal; 44% relapsed after surgery and were

11 combination maintenance, both regimens using steroid withdrawal after 7 days.

12 ablished a mouse PPD model by sudden ovarian steroid withdrawal after hormone-simulated pseudopregnan

13 For noninferiority, rituximab had to permit steroid withdrawal and maintain 3-month proteinuria (mg/

14 vels substantiate the clinical challenges of steroid withdrawal and merit future research.

15 of SD-rATG induction in the context of early steroid withdrawal and tacrolimus minimization or withdr

16 rnate-day doses (1.5 mg/kg/dose), with early steroid withdrawal and tacrolimus or sirolimus maintenan

17 ovement toward minimal immunosuppression and steroid withdrawal and the development of safer and more

18 olled study evaluated safety and efficacy of steroid withdrawal at 2 days in kidney recipients monito

19 tion, tacrolimus, mycophenolate mofetil, and steroid withdrawal by day 5 after transplantation in our

20 conclude that renal transplant recipients on steroid withdrawal by the end of week 1 are not at highe

21 These data show for the first time that steroid withdrawal can be safely accomplished in pancrea

22 Steroid withdrawal causes rapid rebound of inflammation,

23 2 in QbG10-treated patients (n = 33) despite steroid withdrawal, compared with deteriorations observe

24 In 42 (86%) of 49 patients allocated to steroid withdrawal, complete steroid withdrawal was achi

25 ant in kidney transplant recipients on rapid steroid withdrawal does not decrease the progression of

26 Relapses are common after steroid withdrawal, especially with proximal strictures.

27 Early steroid withdrawal (ESW) is a viable maintenance immunos

28 Early steroid withdrawal (ESW) is associated with acceptable o

29 Early steroid withdrawal (ESW) is associated with AR in other

30 Steroid withdrawal from patients taking prednisone for t

31 diagnosed in 21% in control group and 4% in steroid withdrawal group (P<0.01).

32 y recipients were studied; 150 in second-day steroid withdrawal group and 150 in steroid treated grou

33 e in the first year in 25 (53%) of 47 in the steroid withdrawal group compared with 9 (18%) of 50 in

34 (27), 151 (36), and 150 (36) mumol/L in the steroid withdrawal group versus 138 (34), 140 (51), and

35 Participants in the early steroid withdrawal group were significantly more often t

36 Of 22 patients in the steroid withdrawal group, 10 were DSR+ and 12 were DSR-

37 24 mo was 45.3 mL/min/1.73 m 2 in the early steroid withdrawal group, 49.0 mL/min/1.73 m 2 in the st

38 diagnosed in 14% in control group and 16% in steroid withdrawal group.

39 nd 1.8+/-0.9 mg/dl and 61+/-10 mls/minute in steroid withdrawal group.

40 NODM was significantly less in steroid withdrawal group.

41 as 89% and 79% in control and 91% and 78% in steroid withdrawal group.

42 l cholesterol declined about 1 mmol/L in the steroid withdrawal group.

43 of patients deemed not to be candidates for steroid withdrawal (group 2, n=15).

44 Two-day steroid withdrawal in kidney transplant recipients did n

45 of this analysis was to assess the safety of steroid withdrawal in our pediatric renal transplant rec

46 The results of steroid withdrawal in pancreas transplant recipients und

47 These data suggest that steroid withdrawal in pediatric renal transplant patient

48 Past attempts at steroid withdrawal in pediatric renal transplantation ha

49 pression were similar, except for more early steroid withdrawal in the high-dose group.

50 ithout evidence of toxicity while permitting steroid withdrawal in the majority of patients.

51 active antibody, delayed graft function, and steroid withdrawal; in these groups, cytolytic induction

52 Steroid withdrawal is associated with excellent patient

53 Late steroid withdrawal is feasible in most patients with sta

54 posttransplant in kidney recipients on rapid steroid withdrawal is poorly tolerated and does not impr

55 Two-day steroid withdrawal is safe and beneficial in kidney tran

56 It has also been reported that following steroid withdrawal, KS lesions often undergo partial or

57 from TAC, MMF, and steroids to EVR/rTAC and steroid withdrawal maintains immunosuppressive efficacy

58 Steroid withdrawal may be associated with long-term dete

59 DSR before steroid withdrawal may identify a subset of transplant p

60 ved in 58 (47%) patients with a mean time to steroid withdrawal of 15.2+/-8 months (range 4 to 40 mon

61 Therapy is often individualized by steroid withdrawal or addition of belatacept or inhibito

62 Steroid withdrawal patients showed a further rise in mea

63 sts even with successful transplantation and steroid withdrawal protocols.

64 n in pancreas recipients, there was a higher steroid withdrawal rate (p = 0.02), fewer rejection epis

65 An early steroid withdrawal regimen with antithymocyte globulin i

66 the use of maintenance steroids versus early steroid withdrawal remained similar (aOR = 0.711.071.62)

67 ents treated with steroids for relapse after steroid withdrawal responded; 7 patients on additional i

68 r risk have motivated increasing interest in steroid withdrawal (SW).

69 tained, being more evident immediately after steroid withdrawal than at one year.

70 Incorporating a controlled steroid withdrawal, the effects on patient-reported (day

71 Twenty-four hours after steroid withdrawal, the time constant for decay of GABAA

72 tration has risen from 1.28+/-.0.37 prior to steroid withdrawal to 1.64+0.54 at last follow-up (P=0.0

73 ent randomized trial (Belatacept-based Early Steroid Withdrawal Trial, clinicaltrials.gov NCT01729494

74 Topical steroid withdrawal (TSW) is a controversial diagnosis ad

75 t study, we have characterized properties of steroid withdrawal using a pseudopregnant rat model.

76 1.1 years (range 1.0 to 4.8 years), complete steroid withdrawal was achieved in 58 (47%) patients wit

77 ts allocated to steroid withdrawal, complete steroid withdrawal was achieved.

78 Steroid withdrawal was associated with significant reduc

79 A randomised controlled trial of steroid withdrawal was conducted among renal transplant

80 Complete steroid withdrawal was possible in 31 (65%) of the 48 pa

81 Other changes associated with steroid withdrawal were reductions in white cell count a